| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A physiologically-based quantitative systems pharmacology model for mechanistic understanding of the response to alogliptin and its application in patients with renal impairment
|
Shen, Chaozhuang
|
|
|
52 |
1 |
|
article
|
| 2 |
A PopPBPK-RL approach for precision dosing of benazepril in renal impaired patients
|
Vigueras, Guillermo
|
|
|
52 |
1 |
|
article
|
| 3 |
Application of model-informed drug development (MIDD) for dose selection in regulatory submissions for drug approval in Japan
|
,
|
|
|
52 |
1 |
|
article
|
| 4 |
Comparison of the power and type 1 error of total score models for drug effect detection in clinical trials
|
Haem, Elham
|
|
|
52 |
1 |
|
article
|
| 5 |
Do P-glycoprotein-mediated drug-drug interactions at the blood-brain barrier impact morphine brain distribution?
|
Gülave, Berfin
|
|
|
52 |
1 |
|
article
|
| 6 |
Model-informed approach to estimate treatment effect in placebo-controlled clinical trials using an artificial intelligence-based propensity weighting methodology to account for non-specific responses to treatment
|
Gomeni, Roberto
|
|
|
52 |
1 |
|
article
|
| 7 |
Multiorgan-on-a-chip for cancer drug pharmacokinetics-pharmacodynamics (PK-PD) modeling and simulations
|
Mohammed, Abdurehman Eshete
|
|
|
52 |
1 |
|
article
|
| 8 |
No QT interval prolongation effect of sepiapterin: a concentration-QTc analysis of pooled data from phase 1 and phase 3 studies in healthy volunteers and patients with phenylketonuria
|
Gao, Lan
|
|
|
52 |
1 |
|
article
|
| 9 |
Novel endpoints based on tumor size ratio to support early clinical decision-making in oncology drug-development
|
Chakraborty, Shubhadeep
|
|
|
52 |
1 |
|
article
|
| 10 |
QSP modeling of a transiently inactivating antibody-drug conjugate highlights benefit of short antibody half life
|
Khera, Eshita
|
|
|
52 |
1 |
|
article
|
| 11 |
Quantifying natural amyloid plaque accumulation in the continuum of Alzheimer’s disease using ADNI
|
Elhefnawy, Marwa E.
|
|
|
52 |
1 |
|
article
|
| 12 |
Semi-mechanistic population pharmacokinetic modeling of DZIF-10c, a neutralizing antibody against SARS-Cov-2: predicting systemic and lung exposure following inhaled and intravenous administration
|
Kurup, Sree
|
|
|
52 |
1 |
|
article
|
| 13 |
Stronger together: a cross-SIG perspective on improving drug development
|
Fostvedt, Luke
|
|
|
52 |
1 |
|
article
|
| 14 |
Translational pharmacokinetic and pharmacodynamic modelling of the anti-ADAMTS-5 NANOBODY® (M6495) using the neo-epitope ARGS as a biomarker
|
Pereira, Joao N.S.
|
|
|
52 |
1 |
|
article
|
| 15 |
Translational population target binding model for the anti-FcRn fragment antibody efgartigimod
|
Hoefman, Sven
|
|
|
52 |
1 |
|
article
|
Journal description